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Accepted 24 August 2015; Published online 29 August 2015AbstractObjectives: Poor quality of reporting of confounding has been observed in observational studies prior the STrenghtening the Reporting
of Observational studies in Epidemiology (STROBE) statement, a reporting guideline for observational studies. We assessed whether the
reporting of confounding improved after the STROBE statement.
Study Design and Setting: We searched MEDLINE for all articles about observational cohort and caseecontrol studies on interven-
tions with a hypothesized beneficial effect in five general medical and five epidemiologic journals published between January 2010 and
December 2012. We abstracted data for the baseline period before the publication of the STROBE statement (January 2004eApril
2007) from a prior study. Six relevant items related to confounding were scored for each article. A comparison of the median number
of items reported in both periods was made.
Results: In total, 174 articles published before and 220 articles published after the STROBE statement were included. The median num-
ber reported items was similar before and after the publication of the STROBE statement [median, 4; interquartile range [IQR], 3e5 vs.
median, 4; IQR, 3.75e5]. However, the distribution of the number of reported items shifted somewhat to the right (P 5 0.01).
Conclusion: Although the quality of reporting of confounding improved in certain aspects, the overall quality remains
suboptimal.  2016 Elsevier Inc. All rights reserved.
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There is a growing interest into widespread problems
affecting the validity and reliability of published health care
research [1e4]. Inadequate reporting is a widespread prob-
lem and has been frequently observed in publications of
animal and other preclinical studies, observational studies,
diagnostic studies, clinical prediction research, surveys and
qualitative studies, and randomized trials [3]. Several studies
indicate that it is often impossible to replicate studies, partly
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0895-4356/ 2016 Elsevier Inc. All rights reserved.reporting is necessary to enable readers to assess the reli-
ability and validity of study findings. Although poor report-
ing may have some correlation with the risk of bias [8], the
reporting quality of a study does not necessarily reflect the
methodological quality of the study [9,10]. Hence, without
adequate reporting, it is difficult or impossible to assess
the strengths and weaknesses of the study and to replicate
the study. Furthermore, inadequate reporting wastes the time
and resources invested in the conduct of research [3].
Guidelines on the reporting of research can improve
the quality of reporting, especially if those guidelines are
supported and adopted by journals [11e13]. Several guide-
lines have been developed to improve the quality of report-
ing of studies, including CONsolidated Standards of
Reporting Trials (CONSORT), STrenghtening the Report-
ing of Observational studies in Epidemiology (STROBE),
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA), Standards for Reporting of
inical Epidemiology 69 (2016) 217e224What is new?
Key findings
 The quality of reporting of confounding remained
suboptimal after the publication of the STrenghten-
ing the Reporting of Observational studies in
Epidemiology (STROBE) statement.
 Journals that published the STROBE statement and
included an endorsement of the STROBE guide-
lines in their author instructions did have a similar
reporting quality as journals that did neither.
What this adds to what was known?
 Poor quality of reporting of confounding has been
observed prior the publication of the STROBE
statement; this study shows that the quality is still
suboptimal several years after the STROBE
statement.
What is the implication and what should change
now?
 The reporting of confounding may be improved by
better adherence to the STROBE guideline and by
making current and future scientist more aware of
the importance of adequate reporting of confound-
ing. Better adherence to the reporting guideline
may be accomplished by requiring authors to sub-
mit a checklist with sufficient text excerpted from
the manuscript, instead of only page numbers, to
explain how they accomplished all applicable
items.
218 K.B. Pouwels et al. / Journal of ClDiagnostic Accuracy (STARD), Animal Research: Report-
ing of In Vivo Experiments, Standards for Quality
Improvement Reporting Excellence, and Consolidated
Health Economic Evaluation Reporting Standards [14].
A comprehensive list of reporting guidelines can be found
elsewhere (http://www.equator-network.org/http://www.
equator-network.org/) [14]. The STROBE statement was
developed to improve the reporting of observational studies
and published in 2007 [15]. The adoption of this guideline
differs per journal, although it seems intuitive to assume
that more active endorsement would result in better report-
ing quality. Some journals actively endorse the use of
the STROBE guideline and require the submission of
the STROBE checklist (http://www.strobe-statement.org/
fileadmin/Strobe/uploads/checklists/STROBE_checklist_
v4_combined.pdf), such as The BMJ and recently PLOS
Medicine [16,17], whereas other journals only endorse
the use of the STROBE statement in their Instructions forAuthors (e.g., Lancet) or do not mention the STROBE
statement at all (e.g., New England Journal of Medicine).
It is well known that observational studies are prone to
confounding because interventions are often prescribed to
patients based on the perceived risk of the outcome instead
of randomly assigned as in randomized controlled trials
[18,19]. Moreover, especially for preventive interventions,
patients who initiate and adhere to the intervention of inter-
est may be more health conscious, have a more healthy life-
style, and may also adhere better to other preventive
interventions [20,21].
Despite the vulnerability of observational studies to con-
founding, poor quality of reporting of confounding has
previously been observed [22]. Included articles were pub-
lished before the STROBE statement, and it was suggested
that this statement, which was intended to improve the re-
porting of observational studies, could have a considerable
impact on the reporting of confounding [22].
To enable an adequate assessment of the likelihood that a
study is affected by unmeasured or residual confounding,
several items should be reported and discussed. This is
acknowledged by the designers of the STROBE statement,
who included several items related to the reporting of
confounding in the STROBE checklist: item 7 requires that
all potential confounders are clearly defined; item 12
requires that all statistical methods, including those used to
control for confounding are described; item 14a requires that
characteristics of study participants and information on expo-
sures and potential confounders are given; item 16
requires the reporting of unadjusted estimates and, if appli-
cable, confounder-adjusted estimates and their precision
together with a clear description of the confounders that were
adjusted for and why they were included. In addition, the
following items which are more general statements related
to bias may improve the reporting of confounding: item 9 re-
quires that any efforts to address potential sources of bias are
described in the method section, and item 19 requires that the
limitation of the study is discusses, taking into account sour-
ces of potential bias or imprecision, thereby discussing both
the directions as magnitude of any potential bias.
Because multiple items related to confounding are
included in the STROBE statement, we were interested
whether the reporting of confounding improved over time.
Our primary objective was to assess whether the report-
ing of confounding improved in articles after the publica-
tion of the STROBE statement compared with articles
published before that statement. In secondary analyses,
we evaluated whether reporting was better for journals that
published the STROBE statement, endorsed the STROBE
statement in their Instructions for Authors, and/or required
the completion of the STROBE checklist when submitting
an observational study. We hypothesized that the reporting
of confounding would have been improved after publica-
tion of the STROBE guideline, especially in journals that
endorsed the STROBE statement.
219K.B. Pouwels et al. / Journal of Clinical Epidemiology 69 (2016) 217e2242. Methods
As we intended to make a comparison with articles pub-
lished before and after the STROBE statement, similar
methods were used as previously described [22]. We
searched the MEDLINE database to find observational
studies that were published from January 2010 through
December 2012 in the same five epidemiologic journals
and five general medical journals. The five epidemiologic
journal included International Journal of Epidemiology,
Epidemiology, Journal of Clinical Epidemiology, American
Journal of Epidemiology, and Journal of Epidemiology and
Community Health. The five general medical journals
included New England Journal of Medicine, The Lancet,
Journal of the American Medical Association, The BMJ,
and Annals of Internal Medicine. Those journals were
selected in the previous study based on their high-impact
factor [22]. Of these, five journals published the STROBE
statement (The Lancet, The BMJ, Annals of Internal Med-
icine, Epidemiology, and Journal of Clinical Epidemi-
ology). Of the journals that published the STROBE
statement, The Lancet, The BMJ, and Annals of Internal
Medicine also refer to the STROBE statement in their In-
structions for Authors, whereas none of the other journals
did endorse the STROBE statement in their instructions
to authors. The BMJ was the only included journal that
required the completion of the STROBE checklist when
submitting an observational study.2.1. Data selection
The search strategy aimed at identifying observational
cohort and caseecontrol studies that evaluated a hypothe-
sized beneficial (preventive) effect of an intervention on a
clinical outcome. Hence, studies on adverse effects were
excluded. We did not include randomized controlled trials,
meta-analyses, letters, comments, editorials, studies in which
the primary outcome (as indicated by the authors or the
outcome mentioned in the abstract) was intermediate (e.g.,
cholesterol levels instead of cardiovascular disease), noninter-
vention studies (e.g., effect of weather on myocardial infarc-
tion incidence), beforeeafter studies, or non-English studies.
The search strategy is listed in Appendix A at www.
jclinepi.com. In studies with multiple outcomes, we as-
sessed the reporting related to the primary outcome. We
excluded studies for which the allocation of the exposure
of interest was likely determined by a random process
as mentioned in Section 2 or anywhere else in the article
as confounding will likely not play a role in such studies.
For example, we excluded a study in which dispensation
of proprietary vs. generic formulations of antiretroviral
therapy was not driven by patient characteristics, but by
the availability of drugs, with an effort to maintain a given
patient on the same formulation from month to month. This
resulted in a natural experiment that was close to a random-
ized trial, with a small likelihood of confounding.We exported retrieved citations to Refworks (ProQuest,
Ann Arbor, Michigan). Title and abstract screening were
performed including all possibly relevant evaluations for
further review. The full text of all remaining studies was
retrieved and reviewed for eligibility.2.2. Data extraction
Details on a number of basic study characteristics and
items related to reporting of confounding were indepen-
dently extracted by two researchers (K.B.P. and N.N.W.).
Disagreements were resolved by consensus. Basic study
characteristics were journal type (general medical or epide-
miologic), study design (cohort or caseecontrol), publica-
tion year, whether the journal published the STROBE
statement, type of intervention, and type of outcome.
To facilitate a comparison with the previous assessment
of reporting of confounding prior the publication of the
STROBE statement [22], the same information on the
design and analytical details concerning confounding
were extracted (Table 1) [22]. It was assessed whether
the following items were reported: characteristics of key
confounders as well as reasons why potential confounders
were selected for analysis and included in the final model;
methods to control for confounding (e.g., stratification,
multivariate regression, propensity score matching etc.);
and both the crude as well as the adjusted effect estimate,
in case only an adjusted effect estimate was reported, it
was considered sufficient if the crude effect estimate could
be calculated using data from the article. Furthermore, it
was evaluated whether qualitative statements on the likeli-
hood and direction of the potential impact of unmeasured
confounders were reported. Finally, we assessed whether
a quantitative sensitivity analysis to estimate the potential
impact of unmeasured confounders on the effect estimate
was included in the published article.
The original data from the previous study [22] were
obtained to enable a comparison of a period before the
STROBE statement was published (January 2004eApril
2007; previous study) with the period after the STROBE
statement (January 2010eDecember 2012; present study).2.3. Comparisons and data analysis
In primary analysis, a comparison was made between
the quality of reporting of confounding before vs. after
the publication of the STROBE statement.
Three secondary analyses were performed. First, articles
from journals that published the STROBE statementdused
as an indicator that the journal acknowledges the impor-
tance of adequate reportingd(The Lancet, BMJ, Annals
of Internal Medicine, Epidemiology, and Journal of Clinical
Epidemiology) were compared with articles from journals
that did not publish the STROBE statement (American
Journal of Epidemiology, International Journal of Epidemi-
ology, New England Journal of Medicine, Journal of the
Table 1. Frequencies of important items in the reporting of confounding in observational studies
Item
Studies with adequate reporting
(2004e2007, n [ 174) (%)
Studies with adequate reporting
(2010e2012, n [ 220) (%) RR (95% CI)
Reporting of reasons why potential confounders are
selected for analysis
18 (10.3) 55 (25.0) 2.42 (1.49e3.96)
Reporting of reasons to include confounders in the
final modela,b
88 (50.6) 88 (40.0) 0.79 (0.64e0.98)
Reporting of characteristics of key confoundersc 139 (79.9) 175 (79.5) 1.00 (0.90e1.11)
Reporting of any method used to control for
confoundingd
171 (98.3) 218 (99.1) 1.01 (0.98e1.04)
Reporting of both crude and adjusted effect
estimateb
136 (78.2) 160 (72.7) 0.93 (0.83e1.04)
Comment on likelihood unmeasured confoundinge 102 (58.6) 186 (84.5) 1.44 (1.27e1.67)
Qualitative statement direction unmeasured
confoundinge
27 (15.5) 71 (32.2) 2.08 (1.41e3.10)
Quantitative bias analysis for unmeasured
confounding
4 (2.3) 8 (3.6) 1.58 (0.52e4.88)
Abbreviations: RR, relative risk; CI, confidence interval; STROBE, STrenghtening the Reporting of Observational studies in Epidemiology.
a STROBE item 7: clearly define all outcomes exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if
applicable.
b STROBE item 16(a): give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence
interval). Make clear which confounders were adjusted for and why they were included.
c STROBE item 14(a): give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential
confounders; give information separately for cases and controls in caseecontrol studies and, if applicable, for exposed and unexposed groups in
cohort and cross-sectional studies.
d STROBE item 12(a): describe all statistical methods, including those used to control for confounding.
e STROBE item 19: discuss limitation of the study, taking into account sources of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias.
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ology and Community Health).
Second, we compared journals that published the
STROBE statement and included an endorsement of the
STROBE guidelines in their author instructions (The Lancet,
The BMJ, and Annals of Internal Medicine) with journals
that did neither (American Journal of Epidemiology, Interna-
tional journal of Epidemiology, New England Journal of
Medicine, Journal of the American Medical Association,
and Journal of Epidemiology and Community Health).
Third, The BMJ, the only included journal that required
the completion of the STROBE checklist when submitting
an observational study, was compared with the two journals
that only endorsed the STROBE statement in their author
instructions (The Lancet and Annals of Internal Medicine).
This was done to evaluate whether such more active
endorsement of the STROBE statement would result in bet-
ter reporting of confounding.
Our primary outcome consisted of the same eight-item
score that was created and used previously, excluding items
1 and 8 from Table 1 that are not addressed by the STROBE
statement [22]. Hence, a six-item score was created with
equal weights given to each item. For the comparison of
the overall quality of reporting, a comparison was made
between the median number of reported items (maximum
of 6) before and after the STROBE statement using the
ManneWhitney U-test. In addition, relative risks 95% con-
fidence interval (CI) were calculated to represent changes
in the individual items. Statistical analyses were performed
using the R statistical software package version 3.0.2.2.4. Sensitivity analysis
Of the eight items related to confounding that we consid-
ered important, two items are not included in the STROBE
statement. The reason why potential confounders were
selected for analyses and the application of a quantitative
bias analysis are both not mentioned in that guideline.
Therefore, in the primary analysis, we used a six-item score,
excluding the two items that are not addressed by the
STROBE statement. However, because both items are
important for evaluating the likelihood and potential impact
of unmeasured confounding [23e28], we performed a sensi-
tivity analysis in which we used the same eight-item score
that was created and used previously [8], including these
two items.3. Results
The MEDLINE search identified 2,651 publications
(Fig. 1). After screening the titles and abstracts of all
retrieved publications, we reviewed 408 full-text articles
and subsequently included 220 articles in the final analysis
(Appendix B at www.jclinepi.com). Of those studies, 125
(56.8%) were published in general medical journals and
95 (43.2%) in epidemiologic journals. Of the included arti-
cles, 66 were published in 2010, 75 in 2011, and 79 in
2012. There were more cohort studies (181, 82.3%) than
caseecontrol studies (39, 17.7%) included. Among general
medical journals, only 11.2% of studies were caseecontrol
studies. Most studies were published in journals that did not
Fig. 1. Flow diagram for study selection.
221K.B. Pouwels et al. / Journal of Clinical Epidemiology 69 (2016) 217e224publish the STROBE statement (151, 68.6%). In 72 articles
(32.7%), the effects of diets were studied; in 52 (23.6%),
the effects of drugs; in 24 (10.9%), the effects of surgical
procedures; in 27 (12.3%), the effects of medical strategies
(e.g., the association between mechanical ventilation and
survival among patients with acute lung injury); 20
(9.1%) articles described the effects of behavioral interven-
tions (e.g., the effect of physical activity on mortality); 12
(5.5%) reported the effects of vaccination; 7 (3.2%) the ef-
fects of screening or preventive measures, and 6 (2.7%)
about other interventions such as hospital recognition of
nursing excellence.
Table 1 shows the frequencies of items in the reporting
of confounding in observational intervention studies. Low
frequencies were observed for the reporting of reasons whyFig. 2. Histograms of the overall scores for the quality of reporting of confoun
reported for studies published between January 2004 and April 2007. (A) Re
studies published between January 2010 and December 2012. (For interp
referred to the Web version of this article.)potential confounders were selected for analysis, the report-
ing of reasons to include confounders in the final model, re-
porting of comments on the direction of the potential effect of
unmeasured confounding, and the use of sensitivity analysis
to quantify this potential effect (Table 1). When interpreting
these results, it should be noted that the reasons why potential
confounders were selected for analysis and the use of sensi-
tivity analysis to quantify the potential effect of unmeasured
confounding are not included in the STROBE statement.
Nevertheless, compared with the period before the STROBE
statement, the reporting of reasons why potential con-
founders were selected for analysis improved. Other items
that were more frequently reported were comments on the
likelihood of unmeasured confounding, and qualitative state-
ments about the direction unmeasured confounder(s) would
likely bias the results (Table 1). However, reports included
less frequently the reasons to include confounders in the final
model. The other items did not change significantly.
The median number of items reported was similar before
and after the publication of the STROBE statement [before:
median, 4; interquartile range [IQR], 3e5; after: median, 4;
IQR, 3.75e5]. However, the distribution of the number of
items reported shifted somewhat to the right with less arti-
cles with a low number of items and more articles with a
high number of items (Fig. 2, P 5 0.01). When in sensi-
tivity analysis, items 1 and 8 from Table 1 were included
in the summary score, this shift became slightly stronger
(median, 4; IQR, 3e5 vs. median, 4; IQR, 4e5;
P 5 0.0007).
When journals that published the STROBE statement in
2007dused as an indicator that the journal acknowledges
the importance of adequate reportingdwere compared with
journals that did not, median number of items reported
were not statistically significant higher for journals that
published the STROBE statement (median, 4; IQR, 4e5
vs. median, 4; IQR, 3e5; P 5 0.26). Similar results wereding. (B) Blue bars represent the proportion of studies with 0e6 items
d bars represent the proportion of studies with 0e6 items reported for
retation of the references to color in this figure legend, the reader is
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STROBE statement and included an endorsement of the
STROBE guidelines in their author instructions with jour-
nals that did neither (median, 4; IQR, 4e5 vs. median, 4;
IQR, 3e5; P 5 0.33). Articles from the BMJ, the only
included journal that required the submission of a
completed STROBE checklist, did not have a better report-
ing of confounding than journals that endorsed the
STROBE statement in their author instructions but did
not require the completion of the checklist (median, 4;
IQR, 4e5 vs. median, 4; IQR, 3.5e5; P 5 0.72).4. Discussion
Although the quality of reporting of confounding in ar-
ticles on observational interventions improved in certain
aspects because the introduction of the STROBE statement,
this study shows that the overall quality of reporting re-
mains suboptimal.
Quantitative bias analyses were still very rare (reported in
3.6% of the articles), whereas such analyses can be very
informative and potentially avoid unnecessary harm to pa-
tients and waste of time and resources invested in new
research [22]. Despite the increasing number of articles in
the literature emphasizing the importance of quantitative bias
analysis [25,28e34], such analyses are still rarely applied as
observed previously [22]. Although we acknowledge that
there are situations where quantitative bias analysis may
not be very useful, such as analyses with very wide conven-
tional confidence intervals, we do think that the STROBE
statement should ask authors to report on quantitative bias
analysis ordif not conducteddreport why not.
It is difficult to imagine that the current practice of system-
atically ignoring sources of uncertainty other than randomer-
ror is theway forward. Especially with the increasing interest
in and use of big data [35,36], very narrow confidence inter-
vals can be expected. Without a quantitative bias analysis,
researchers and decisionmakers risk largely underestimating
the true uncertainty in these circumstances. In the future,
reporting of quantitative bias analysis and the other items
from our Table 1 enables a better assessment of the risk and
impact of confounding using, for example, the currently
developed ‘‘Cochrane risk of bias assessment tool for non-
randomized studies of interventions’’ [37].
The reasons why potential confounders were selected for
analysis and included in the final analysiswere also frequently
missing from the included articles. Reporting of both items is
important, as causal inference from observational data
depends not only on the data, but also on the design of the
study and subject-specific knowledge [26e28]. Without a
structured way to obtain subject matter knowledge, it will
be difficult to define a causal structure, a prerequisite to
adequately select a variable as a potential confounder
[26e28]. Hernan et al. previously showed the importance of
communicating which strategy is used to select theconfounders included in the final model [27]. Ideally, causal
diagrams are used to summarize and communicate the causal
structure assumed by the researchers. Of the articles in the
2010e2012 cohort, 0.9% included a causal diagram. Such
diagrams may also enable the researcher to determine the
direction of the bias caused by unmeasured confounding
[38], another item that was frequently not reported.
Reporting of both crude and adjusted effect estimates
remained similar. If both effect estimates are reported,
readers can judge by how much, and in what direction, po-
tential confounders changed the effect estimate [39].
Together with a distribution of the confounders among
exposed and unexposed or cases and controls, this informa-
tion can be used to understand the data behind the reported
associations. Unfortunately, almost 20% of the included
studies did not report the characteristics of all key con-
founders. Only the reasons why potential confounders are
selected for analysis (item 1), comments on likelihood of
unmeasured confounding (item 6), and qualitative state-
ments about the direction of unmeasured confounding (item
7) were more frequently reported over time.
This is the first study that evaluated whether the report-
ing of confounding improved after the publication of the
STROBE statement. Moreover, this is the first study that
evaluated whether the reporting of confounding is better
in journals with a more active endorsement of the STROBE
guideline.
This study has some potential limitations. Although
most evaluated items are included in the STROBE check-
list, the application of a quantitative bias analysis and an
item about the reason why potential confounders are
selected for analysis are not mentioned in that guideline.
Therefore, one may expect that these items would not in-
crease substantially over time as a result of the STROBE
statement. However, after including both items, the differ-
ence before and after the STROBE statement became larger
instead of smaller, indicating that including these items
would not result in an underestimation of the impact of
the STROBE statement.
We focused on studies published in a selection of
high-impact general medical and epidemiologic journals.
Such high-impact general journals may have a better re-
porting quality than lower impact and specialist journals
[40], resulting in an overestimate of the quality of reporting
of confounding in all published studies on observational
medical interventions.
The observational nature of the beforeeafter comparison
may have masked effects of the STROBE guideline, due to
underlying trends. Because we were mainly interested in the
question whether the reporting improved since the previous
study that was performed prior the STROBE statement [22],
we did not directly evaluate the impact of the STROBE
statement [15], the launch of the EQUATOR Network and
its activities [14], the previous study showing poor reporting
of confounding in observational research [22], or other arti-
cles that showed the importance of adequate reporting or the
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using for example a time-series analysis. For such an anal-
ysis, as done by Bastuji-Gain et al. [46], the potential lag
time between implementation and effect would be ideally
known, including other events and interventions happening
in between plus the exact dates. Moreover, there was no
trend seen in the previous study in the median number of
items reported over time using data from 2004 to 2007
[22] nor in the years 2010 to 2012 (2010: 4; IQR, 4e5;
2011: 4; IQR, 3e5; 2012: 4; IQR, 4e5).
Our data are in agreement with previous studies that
showed that especially the reporting of selection of con-
founders for analysis needs improvement [22,47e49].
Moreover, in agreement with other studies [22], key issues
related to unobserved confounding are not addressed and/or
underreported. Although there is evidence that reporting
guidelines such as the CONSORT and STARD statement
improve the completeness of reporting [50e52], the effect
of the STROBE statement on the quality of reporting is less
clear [44,46,52]. Despite we did find that the reporting of
confounding improved slightly over time and was better af-
ter than before the STROBE statement was published, jour-
nals that published the STROBE statement or were more
actively endorsing the STROBE statement did not have a
statistically significant better reporting of confounding.
This finding is in agreement with a recent systematic re-
view that did not find a clear relationship between journals’
endorsement of reporting guidelines (BMJ economic
checklist, CONSORT for harms, PRISMA, QUOROM,
STARD, STRICTA, and STROBE) and the completeness
of reporting [52].
In conclusion, reporting of confounding in articles on
observational interventions remained suboptimal. Although
we acknowledge that improving the quality of reporting of
confounding does not solve the whole problem of published
research that cannot be replicated and for which it is un-
clear how reliable and valid the study finding are, there is
still room and need for improvement. How such improve-
ments should be accomplished remains a difficult issue.
Publishing the STROBE statement or endorsing it in the in-
structions for authors does not seem to be enough. The
recently implemented strategy of PLOS Medicine is an
interesting solution [17]. Requiring authors to submit a
checklist with sufficient text excerpted from the manuscript
to explain how they accomplished all applicable items [17]
may results in better adherence to the guideline. In addition,
adequate reporting and knowledge about the existence of
the different reporting guidelines listed on the EQUATOR
network Web site should preferably become part of the core
training of current and future scientists, to make them more
aware of the importance of adequate reporting already at
the beginning of their study. Furthermore, we would like
to encourage research into the development and evaluation
of strategies to improve the quality of reporting, thereby
reducing the waste.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2015.08.009.References
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